Ampulla of Vater Carcinoma

Germline pathogenic variants in the HR pathway genes drive oncogenesis in a large subset of PAMPCAs. These findings highlight the importance of germline genetic testing for patients with PAMPCA for informing therapy and assessing familial risk.

Concurrent normal CA19-9 and DUPAN-2 levels independently predicted favorable outcomes. Combined preoperative biomarker assessment may contribute to prognostic stratification of BTCs, including among patients with Lewis antigen negativity or impaired FUT3 function.

P=N/A, N=420, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting

EMSA further demonstrated that hydroxymethylated CpG sites within the VCAN promoter specifically recruited MeCP2, which interacted with CREB to activate VCAN transcription. These findings reveal a dual role of MeCP2: its loss contributes to epithelial heterogeneity, whereas its retained function in CAFs promotes stromal remodeling through VCAN activation.

P2, N=54, Recruiting, Yale University | Not yet recruiting --> Recruiting

A novel genetically engineered mouse model that mimics gastric-type and intestinal-type adenomas and gastric-type SIAC/EDA is reported. Spatial transcriptomics provided a detailed understanding of cellular differentiation lineages, cancer microenvironment related to SIAC subtypes and driving pathways that may be leveraged to identify new molecular tools for pathologic diagnosis and potential targets for precision cancer therapies.

No adjuvant therapy was administered due to the absence of residual disease and actionable mutations. This case highlights the broad tumor spectrum in NF1 and underscores the importance of comprehensive imaging, multidisciplinary management, and genetic testing for optimal outcomes.

P=N/A, N=15, Recruiting, University of California, Irvine | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026

P=N/A, N=360, Recruiting, Cedars-Sinai Medical Center | Trial completion date: Jun 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Jan 2027

In selected fit patients, modified FOLFIRINOX may address mixed phenotypes...Research priorities include ampulla-enriched umbrella trials, explicit AC subcohorts in tissue-agnostic studies, and ctDNA-informed endpoints. This lineage-first, mutation-fast paradigm supports precision care and evidence generation in AC.

Recurrence is predominantly systemic and driven by nodal status and CA19‑9, adjuvant chemotherapy mitigates distant failure-particularly in N1-and the identification of delayed gastric emptying as an independent predictor underscores the oncologic importance of perioperative optimization; histologic subtype was not independently prognostic.

P=N/A, N=182, Not yet recruiting, Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital; Department of Gastroenterology, The First Medical Center of